Home > ASH 2016 Ian Flinn Interview
Haematological Malignancies, Lymphoma

ASH 2016 Ian Flinn Interview

Published Online: December 12th 2016

 

Dr Ian Flinn discusses the use of duvelisib in relapsed refractory indolent non-Hodgkin lymphoma and the findings of the DYNAMO study. He also discusses the results of the polatuzumab vendotin in combination with obinutuzumab study, presented at ASH 2016.
FILMED AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING 2016, SAN DIEGO, CALIFORNIA, US

Related Videos In Lymphoma
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar